Sarepta Therapeutics
SRPT
$22.02
+5.16%
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD). It markets several approved DMD treatments, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and the gene therapy ELEVIDYS, positioning itself as a leader in the DMD space. The current investor narrative centers on the commercial uptake of ELEVIDYS and the company's path to sustained profitability, as recent quarters have shown volatile revenue and profitability swings, with a significant net loss in Q4 2025 despite earlier profitability in 2024. The stock's recent price surge of over 40% in the past month suggests renewed optimism, likely tied to pipeline updates or commercial progress, though the company faces ongoing challenges in managing costs and achieving consistent financial performance.…
SRPT
Sarepta Therapeutics
$22.02
Investment Opinion: Should I buy SRPT Today?
Based on the data, I rate SRPT a Hold. The consensus rating is Hold with an average price target of $22.26, which is nearly identical to the current price of $22.50, implying minimal upside. The thesis is that while the company has promising products like ELEVIDYS, its financial instability and execution risks justify a cautious stance.
Sign up to view all
SRPT 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the low forward PE and recent price surge suggest potential upside, the severe revenue volatility and margin collapse in Q4 2025 introduce significant uncertainty. The stock's valuation discount to peers may be justified by its inconsistent profitability. To upgrade to bullish, we would need to see stable revenue growth and margin recovery in the next two quarters; to downgrade to bearish, further deterioration in cash flow or negative clinical news would be required.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sarepta Therapeutics's 12-month outlook, with a consensus price target around $22.26 and implied upside of +1.1% versus the current price.
Average Target
$22.26
0 analysts
Implied Upside
+1.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$5 - $38
Analyst target range
With 23 analysts covering the stock, the consensus recommendation is 'Hold' (mean rating 2.67 on a 1-5 scale), and the average price target is $22.26, which is essentially in line with the current price of $22.50, implying a negligible 1.1% downside. The distribution of ratings includes a mix of Buy, Hold, and Sell, with recent actions from firms like Needham (Underperform) and Citigroup (Sell) contrasting with Outperform ratings from Oppenheimer and Mizuho, reflecting divergent views on the company's prospects. The target range spans from a low of $5.00 to a high of $38.00, a wide spread that underscores the high uncertainty surrounding the stock; the low target likely assumes continued commercial setbacks or pipeline failures, while the high target anticipates successful execution of ELEVIDYS and margin recovery. The recent price surge of 41% in the past month suggests that some analysts may be revising their targets upward, but the consensus remains cautious, indicating that the market is still weighing the company's potential against its execution risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: SRPT Investment Factors
Sarepta presents a high-risk, high-reward opportunity. The bull case hinges on ELEVIDYS commercial success and a return to profitability, supported by a low forward PE and strong liquidity. However, the bear case is equally compelling, with severe revenue volatility, negative cash flow, and a consensus Hold rating. Currently, the bearish evidence is slightly stronger due to the recent Q4 loss and margin collapse, but the stock's low valuation and recent momentum suggest the market is beginning to see potential. The most critical tension is whether Sarepta can stabilize its revenue and margins while scaling ELEVIDYS; if it succeeds, the stock could re-rate significantly, but failure could lead to further downside.
Bullish
- ELEVIDYS commercial momentum: The stock surged 41.2% in the past month, reflecting renewed investor optimism about ELEVIDYS uptake and pipeline progress. This recent price action suggests the market is beginning to price in a successful commercial launch, which could drive significant revenue growth.
- Forward PE implies earnings recovery: With a forward PE of 8.76x based on estimated EPS of $1.16, the market expects a dramatic earnings rebound from the current negative trailing EPS of -$3.02. If Sarepta achieves these estimates, the stock could be undervalued relative to its growth potential.
- Strong liquidity position: The current ratio of 2.32 indicates the company has ample short-term liquidity to fund operations and R&D. This financial buffer reduces near-term bankruptcy risk and provides flexibility to invest in its pipeline.
- Multiple approved DMD products: Sarepta has four approved DMD treatments, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, creating a diversified revenue base within the DMD market. This portfolio reduces reliance on any single product and provides multiple growth drivers.
Bearish
- Revenue volatility and Q4 decline: Q4 2025 revenue of $442.9 million fell 32.7% year-over-year, and gross margin collapsed to just 10.0% from over 80% in prior quarters. This extreme volatility raises concerns about the sustainability of the company's commercial operations and product mix.
- Negative free cash flow and losses: Trailing twelve-month free cash flow was -$317.4 million, and the company reported a net loss of $282.8 million in Q4 2025. The inability to generate positive cash flow consistently indicates ongoing financial strain.
- High debt-to-equity ratio: The debt-to-equity ratio of 0.91 is elevated for a biotech, increasing financial risk. Combined with negative ROE of -62.5%, the company's capital structure is a concern if losses persist.
- Analyst consensus is Hold with minimal upside: The average analyst price target of $22.26 is essentially in line with the current price of $22.50, implying a negligible 1.1% downside. This suggests that analysts see limited near-term upside, reflecting uncertainty about execution.
SRPT Technical Analysis
Sarepta's stock is in a strong recovery phase, having surged 21.9% over the past year, with the current price of $22.50 sitting at 88.7% of its 52-week range (low $14.68, high $25.32). This positioning near the upper end of the range indicates robust momentum, though it also raises the risk of overextension after such a rapid advance. The stock's beta of 0.261 suggests it is significantly less volatile than the broader market, which is unusual for a biotech and may reflect its relatively stable revenue base from approved products.
Beta
0.26
0.26x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$15-$25
Price range past year
Annual Return
+24.8%
Cumulative gain past year
| Period | SRPT Return | S&P 500 |
|---|---|---|
| 1m | +28.2% | -1.4% |
| 3m | +46.8% | +3.3% |
| 6m | +34.3% | +15.1% |
| 1y | +24.8% | +17.2% |
| ytd | +3.3% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRPT Fundamental Analysis
Revenue has been highly volatile, with Q4 2025 revenue of $442.9 million representing a 32.7% year-over-year decline from the prior year's Q4, and the most recent quarter's gross margin collapsed to just 10.0% (gross profit of $44.2 million) versus 80%+ in earlier quarters, likely due to one-time costs or product mix shifts. The company reported a net loss of $282.8 million in Q4 2025 (EPS -$2.74), a stark reversal from the profitable Q2 2025 (net income of $196.9 million) and Q4 2024 (net income of $159.0 million), highlighting the lumpiness of its earnings. Over the trailing twelve months, free cash flow was negative at -$317.4 million, and the company's ROE is deeply negative at -62.5%, reflecting the recent losses and a high debt-to-equity ratio of 0.91, though the current ratio of 2.32 indicates adequate short-term liquidity.
Quarterly Revenue
$442934000.0B
2025-12
Revenue YoY Growth
-32.7%
YoY Comparison
Gross Margin
10.0%
Latest Quarter
Free Cash Flow
$-317427000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRPT Overvalued?
Given the negative trailing EPS (-$3.02), the price-to-earnings ratio is not meaningful, so I selected the price-to-sales ratio as the primary valuation metric; the current PS ratio of 1.03x is based on trailing revenue, while the forward PE of 8.76x implies the market expects a dramatic earnings recovery, as analysts project EPS of $1.16 for the next fiscal year. The stock trades at a significant discount to its historical PS ratios, which ranged from 5x to over 40x in the past two years, suggesting the market is pricing in lower growth or higher risk. Compared to the biotechnology industry average PS ratio of approximately 5x (based on typical sector data), Sarepta's 1.03x represents a 79% discount, which may be justified by its inconsistent profitability and competitive pressures in the DMD market.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~89x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-3.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company's revenue is highly volatile, as evidenced by Q4 2025's 32.7% year-over-year decline and a gross margin that plummeted to 10.0% from over 80% in earlier quarters. This volatility, combined with a net loss of $282.8 million in Q4 2025 and negative free cash flow of -$317.4 million over the TTM, indicates that the company is not yet on a stable financial footing. The high debt-to-equity ratio of 0.91 and negative ROE of -62.5% further underscore the financial strain, although the current ratio of 2.32 provides some short-term liquidity cushion.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of -$317.4 million and a high debt-to-equity ratio of 0.91 could lead to liquidity issues if losses persist. 2) Operational risk: revenue volatility, as seen in Q4 2025's 32.7% YoY decline and gross margin collapse to 10.0%, indicates unstable commercial performance. 3) Competitive risk: the DMD market is competitive, and new therapies could erode Sarepta's market share. 4) Regulatory risk: any safety or efficacy issues with ELEVIDYS or other products could lead to setbacks. The most severe risk is a combination of these factors leading to a sustained downturn, potentially pushing the stock to the analyst low target of $5.
The 12-month forecast is uncertain, with three scenarios: Bull case (30% probability) targets $30-$38, driven by strong ELEVIDYS uptake and profitability. Base case (45% probability) targets $20-$25, assuming revenue stabilization and margin recovery. Bear case (25% probability) targets $5-$15, if ELEVIDYS fails and losses continue. The base case is most likely, given the current Hold consensus and average target of $22.26. The key assumption is that Sarepta can stabilize its revenue and margins while growing ELEVIDYS.
SRPT appears undervalued on a forward basis, with a forward PE of 8.76x, but this is misleading given the negative trailing EPS of -$3.02. The PS ratio of 1.03x is a 79% discount to the biotech industry average of ~5x, and the stock trades well below its historical PS range of 5x-40x. This deep discount suggests the market is pricing in significant risks, such as revenue volatility and competitive pressures. The market expects a dramatic earnings recovery, as implied by the forward PE, but if that recovery fails to materialize, the stock could be fairly valued or even overvalued.
SRPT is not a clear buy at current levels. The average analyst target of $22.26 offers only 1.1% downside, indicating limited upside potential. The stock trades at a forward PE of 8.76x, which is low, but this is based on optimistic earnings estimates that may not materialize given the recent Q4 loss. The biggest downside risk is a continued decline in revenue and margins, which could push the stock toward the 52-week low of $14.68 or lower. For risk-tolerant investors who believe in ELEVIDYS, it could be a speculative buy, but for most, a Hold is more appropriate until financial stability is demonstrated.
SRPT is more suitable for long-term investment, given its speculative nature and high volatility. The stock's beta of 0.261 is low, but its fundamentals are unstable, making short-term trading risky. The company is in a growth phase with potential for significant upside if ELEVIDYS succeeds, but this requires patience. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature and financial performance to stabilize. Short-term traders may find opportunities in the stock's price swings, but the risk of adverse news is high.
